Cagrilintide (AM833) vs Survodutide (BI 456906)
Updated November 4, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Cagrilintide (AM833) and Survodutide (BI 456906) (also searched as Survodutide (BI 456906) vs Cagrilintide (AM833)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Cagrilintide (AM833) centers on metabolic, while Survodutide (BI 456906) leans toward metabolic. On indexed research, Survodutide (BI 456906) is ahead (Cagrilintide (AM833): 22 studies, Human clinical; Survodutide (BI 456906): 30, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Cagrilintide (AM833) is strongest for metabolic; Survodutide (BI 456906) for metabolic.
- •Evidence: Cagrilintide (AM833) Human clinical (22 studies) vs Survodutide (BI 456906) Human clinical (30).
- •Check the FDA-approval status chips above before assuming a legal use pathway.
Effect profiles, overlaid
At a glance
Amylin analog | Obesity and type 2 diabetes
Dual Agonist | Obesity and metabolic disorders
Cagrilintide (AM833) vs Survodutide (BI 456906): side-by-side
| Metric | Cagrilintide (AM833) | Survodutide (BI 456906) |
|---|---|---|
| Class | Metabolic | Metabolic |
| Regulatory status | FDA-approved | Research use only |
| Evidence grade | Human clinical | Human clinical |
| Studies indexed | 22 | 30 |
| Research level | FDA Approved | Well Studied |
| Strongest effect | Metabolic & appetite | Metabolic & appetite |
| Healing & recovery | 1.0▲ | 1.0▲ |
| Muscle & body comp | 1.0▲ | 1.0▲ |
| Metabolic & appetite | 5.0▲ | 5.0▲ |
| Neuro & mood | 2.0▲ | 1.0 |
| Sleep & circadian | 1.0▲ | 1.0▲ |
| Inflammation & immune | 1.0 | 2.0▲ |
| Skin & aesthetics | 3.0▲ | 3.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Cagrilintide (AM833) | Survodutide (BI 456906) |
|---|---|---|
| Mechanism | Long-acting amylin analog | GLP-1/glucagon receptor agonist |
| Route | Subcutaneous injection | Subcutaneous injection |
| Half-life | ~7–8 days | — |
| Duration of action | Weekly dosing (investigational) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Cagrilintide (AM833)?
Cagrilintide (AM833) is a long-acting amylin analog investigated for once-weekly subcutaneous use in obesity and type 2 diabetes, most notably combined with semaglutide as CagriSema.
Full Cagrilintide (AM833) profile, mechanism & studies →What is Survodutide (BI 456906)?
Survodutide (BI 456906) is an investigational dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This peptide is primarily being studied for its potential in treating obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The dual action of Survodutide is designed to enhance weight loss while also improving glycemic control, which is particularly relevant for individuals with type 2 diabetes and related metabolic disorders.
Full Survodutide (BI 456906) profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~1.0/5 |
| Muscle | Even | Both ~1.0/5 |
| Metabolic | Even | Both ~5.0/5 |
| Neuro | Cagrilintide (AM833) | 2.0/5 effect signal |
| Sleep | Even | Both ~1.0/5 |
| Inflammation | Survodutide (BI 456906) | 2.0/5 effect signal |
| Skin | Even | Both ~3.0/5 |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Cagrilintide (AM833) and Survodutide (BI 456906)?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because at least one is a research-use compound, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Cagrilintide (AM833) vs Survodutide (BI 456906): side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Cagrilintide (AM833) has 22 approved studies indexed (Human clinical), and Survodutide (BI 456906) has 30 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Cagrilintide (AM833) or Survodutide (BI 456906) better?
It depends on your goal. Cagrilintide (AM833) is strongest for metabolic; Survodutide (BI 456906) for metabolic. Survodutide (BI 456906) has more indexed studies (30). See the goal-by-goal breakdown above.
Is Cagrilintide (AM833) or Survodutide (BI 456906) better for weight loss?
They score similarly on the metabolic/appetite axis in the community data.
Is Cagrilintide (AM833) or Survodutide (BI 456906) better for muscle?
Both land close on the muscle & body-composition axis.
Which has more research, Cagrilintide (AM833) or Survodutide (BI 456906)?
Cagrilintide (AM833) has 22 approved studies indexed (Human clinical); Survodutide (BI 456906) has 30 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack Cagrilintide (AM833) and Survodutide (BI 456906)?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Cagrilintide (AM833) vs Survodutide (BI 456906)?
Cagrilintide (AM833): no community-reported effects logged yet. Survodutide (BI 456906): none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Cagrilintide (AM833) or Survodutide (BI 456906) FDA-approved?
Cagrilintide (AM833) is FDA-approved. Survodutide (BI 456906) is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Survodutide (BI 456906) better than Cagrilintide (AM833)?
For metabolic, Survodutide (BI 456906) has the edge; for metabolic, Cagrilintide (AM833) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Approval status varies (see the chips at the top). FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 4, 2026.